
Accuray (ARAY) Stock Forecast & Price Target
Accuray (ARAY) Analyst Ratings
Bulls say
Accuray is a radiation oncology company that develops and sells precise treatment solutions for cancer patients, with its technology, the CyberKnife, being a key competitor in the market. However, lower revenue and higher costs for logistics and parts may impact the company's product and service gross margins, and lumpy quarters and geopolitical uncertainty make it difficult to forecast Accuray's results. Despite trading below its peers and possessing strong technology, Accuray may face challenges in the near future due to macroeconomic factors and operational execution.
Bears say
Accuray is facing numerous challenges as they struggle with declining revenue, geopolitical uncertainty, and a lack of progress on operating improvements and profitability metrics. While efforts have been made to cut costs and improve profitability, it does not appear to be enough to offset the impact of these challenges. Unfortunately, with the current market conditions and lack of visibility into a potential turnaround, it may be best to take a neutral stance on the stock.
This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.
Accuray (ARAY) Analyst Forecast & Price Prediction
Start investing in Accuray (ARAY)
Order type
Buy in
Order amount
Est. shares
0 shares